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ABSTRACT 
The purpose of this study is to investigate the direct effect of amitraz, a 
formamidine insecticide/acaricide, and its active metabolite BTS 27271 on insulin 
and glucagon secretions from the perfused rat pancreas. Amitraz and BTS 27271 
(10-8, 10-7, 10-6, or 10-5 M) inhibited insulin secretion in a concentration-dependent 
manner. Amitraz increased glucagon secretion at 10-5 M, whereas BTS 27271 
increased glucagon secretion at 1 o-6 and 1 o-5 M. Amitraz and BTS 27271-induced 
decreases in insulin secretion and increases in glucagon secretion were not 
abolished during the 10-min washout period . Both amitraz and BTS 27271 (10-7 , 
10-6 , or 10-5 M) inhibited arginine-induced insulin secretion and enhanced arginine-
induced glucagon secretion. ldazoxan, an a2N2o-AR antagonist, prevented the 
inhibitory effect of amitraz on insulin secretion in a concentration-dependent manner, 
but prazosin, an a 1- and a 2812c-AR antagonist, failed to antagonize the effect of 
amitraz. These results suggested that: 1) amitraz and BTS 27271 inhibit insulin and 
stimulate glucagon secretion from the perfused rat pancreas, 2) amitraz inhibits 
insulin secretion by activation of a 2N 2o-ARs, and 3) amitraz and BTS 27271 may 
have a high binding affinity to a2-ARs of the pancreatic islets which may be 
responsible for these effects. 
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REVIEW OF LITERATURE 
Amitraz (N'-[2,4-dimethylphenyl]-N-[(2,4-dimethylphenyl)imino]-N-
methylmethanimidamide) is an insecticide/acaricide that belongs to the formamidine 
family. 
Amitraz is widely used to treat mites and ticks in dogs (Mitra et al., 1993; 
Dass, 1996), cattle (Curtis, 1985; Mitra et al., 1993; Morrow et al., 1993; Kagaruki, 
1996), pigs (Johansson et al., 1980; Curtis, 1985), camels (Jacquiet, 1994), sheep 
(Mitra et al., 1993), and goats (Wright et al. , 1988). Amitraz is one of the most 
widely used therapies for canine demodicosis (Davis, 1985; Duclos et al., 1994; 
Medleau and Willemes, 1995; Ristic et al., 1995; Mojzisova et al., 1997). 
Demodicosis in goats (Fleisher et al., 1996), ferrets (Noli et al.; 1996), golden 
hamsters (Hasegawa, 1995), and cats (Crown and Campbell, 1988) is also treated 
with amitraz. In addition, amitraz is used to kill arthropods in agricultural and 
horticultural plants (e.g., pear paylla, whitefly on cotton, tetanychid and eriophyid 
mites on fruits, citrus, and ornamental, and eggs and neonate larvae of cotton 
bollworm and tobacco budworm) (Farm Chemicals Handbook, 1996). 
Physical and chemical characteristics of amitraz 
Amitraz is a highly lipid-soluble compound; thus, it is rapidly absorbed through 
the cutaneous route (Hsu and Schaffer, 1988; Dobozy, 1990; Aydin et al., 1997), 
which makes it potentially hazardous to veterinarians, animal caretakers, and pet 
owners. Amitraz residue may be present in fruits and crops when amitraz is used as 
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a pesticide in agronomy and horticulture; thus, it poses a potential hazard to the 
consumers. Amitraz is not stable under acidic conditions. 
Metabolism of amitraz 
Amitraz (Fig .1, I) is degraded into N'-[2,4-dimethylphenyl]-N-
methylformamidine (BTS 27271 , Fig .1, II), and 2,4-dimethylformanilide (Fig.1, Ill). 
BTS 27271 is degraded into 2,4-dimethylformanilide and the latter is further 
degraded into 2,4-dimethylaniline (Fig .1, IV), and 4-formamido-3-methylbenzoic acid 
(Fig.1, V). Finally, derivatives IV and V are converted to 4-amino-3-methylbenzoic 
acid (Fig.1, VI). All of these compounds are found in tissues (kidney, intestine, lung, 
blood, heart, spleen, and brain) in low amounts (not more than 25 ppb), and are 
concentrated in the liver 96 h after amitraz administration (Knowles and Benezet, 
1981 ). 
Amitraz is rapidly absorbed , distributed, metabolized, and eliminated primarily 
via urine when administered orally (5 mg/kg) to rats . Urinary elimination was 77.6% 
for amitraz and 88.7% for BTS 27271 , while only 8.9% of amitraz and 4.1 % of BTS 
27271 were eliminated via feces by 96 h post-treatment (Knowles and Benezet, 
1981). Oral administration of amitraz (100 mg/kg) to dogs yields a peak of plasma 
concentration after 5 hand a half-life of 24 h (Hugnet et al. , 1996). 
Amitraz is degraded into BTS 27271 when given IV (1 mg/kg) to ponies and 
sheep. The rate of amitraz metabolism is different in the two species; it is 
undetectable in plasma 5 min following administration in sheep, while it is still 
detectable for 90 min in ponies. Differences between sheep and ponies in 
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Fig. 1. Metabolic pathway of amitraz in rats. I) Amitraz, II) N'-[2,4-dimethylphenyl]-
N-methylformamidine (BTS 27271 ), Ill) 2,4-dimethylformanilide, IV) 2,4-
dimethylaniline, V) 4-formamido-3-methylbenzoic acid, and VI) 4-amino-3-
methylbenzoic acid (from Knowles and Benezet, 1981). 
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in pharmacokinetics were observed when BTS 27271 was given IV (0.68 mg/kg), 
with sheep having a larger volume of distribution and faster body clearance than 
ponies (Pass and Mogg, 1995). Labeled amitraz ([1 4C] amitraz) in Boophilus 
microplus larvae (cattle tick) is degraded into BTS 27271 and 2,4-
dimethylformanilide in different ratios (Fig. 1, II and Ill). 2,4-dimethylformanilide and 
2,4-dimethylaniline are found with other unidentified polar and non-polar metabolites. 
From identified compounds, only amitraz and BTS 27271 are toxic to the larvae 
(Schuntner and Thompson, 1978). BTS 27271 was more potent than amitraz with 
regard to miticidal activity (Schuntner and Thompson, 1978) and mammalian toxicity 
(Pass and Mogg, 1991; Chen and Hsu, 1994). 
Mechanism of antiparasitic action of amitraz 
The mechanisms by which formamidines kill arthropods are not completely 
understood, however the formamidines mimic the action of octopamine and have a 
high affinity for octopamine receptors (Evans, 1980; Singh et al., 1981 ; 
Hashemzadeh et al. , 1985; Roder, 1995). 
Octopamine in invertebrates and mammals 
The biogenic amine octopamine (p-hydroxyethanolamine) (Fig . 2) was first 
discovered in the posterior salivary glands of the octopus (Erspamer and Boretti, 
1951 ). Octopamine was found in high concentrations in the nervous system of all 
invertebrates examined (Axelrod and Saavedra, 1977; Orchard, 1982; Evans, 1985; 
Saavedra, 1989). Unlike mammals, little or no catecholamines (epinephrine and 
norepinephrine) are present in invertebrates (Evans, 1985). Very low concentrations 
of octopamine have been found in 
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Fig. 2. Synthesis pathway of octopamine. The reaction is catalyzed by the following 
enzymes: DD, DOPA decarboxylase or aromatic amino acid decarboxylase; DBH, 
dopamine (tyramine) P-hydroxylase; and PNMT, Phenylethanolamine-N-methyl-
transferase (from Evans, 1985). 
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the peripheral tissues and brain of mammals (Molinoff et al., 1969; Molinoff and 
Axelrod, 1972; Saaverda and Axerlod, 1973). However, in mammals the turn over of 
octopamine is very rapid (Brandau and Axelord, 1972; Saavedra, 1989). 
Synthesis and degradation of octopamine 
In the nervous system of vertebrates, octopamine is synthesized from 
tyrosine and/or tyramine (Brandau and Axelord, 1972; Saavedra and Axelrod, 1976; 
Axelord and Saavedra, 1977). Decarboxylation of tyrosine by DOPA decarboxylase 
(DD) (Fig. 2) leads to the formation of tyramine. Octopamine is formed through p-
hydroxylation of tyramine (Fig. 2), and by an unusual route via dehydroxylation of 
epinephrine and norepinphrine (Brandau and Axelord, 1972). The same metabolic 
pathway for octopamine was found in the nervous systems of several invertebrates 
such as the locust, moth, and fruitfly (Evans, 1985). 
Metabolism of octopamine 
Octopamine is metabolized by several routes including: 1) oxidative 
deamination of octopamine by monoamine oxidase (MAO) to form p-
hydroxymandelic acid (Fig. 3). Oxidative deamination is the most common route for 
octopamine in mammals and most invertebrates (Molinoff et al., 1969). Injection of 
a MAO inhibitor causes a marked elevation of octopamine in rat and mouse brain 
and peripheral tissues (Brandau and Axelord, 1972; Harmer and Horn, 1976). 2) N-
acetylation of octopamine by N-acetyltransferase to form N-acetyloctopamine (Fig. 
3) is a major metabolism route in some invertebrates such as insects (Evans, 1985). 
This route was also demonstrated in mammalian tissues (Wu and Boulton, 1979; 
Yang and Neff, 1976). 3) sulfate and p-alanine conjugation (Fig. 3) are an important 
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Fig. 3. The possible routes of metabolism of octopamine. 1) monoamine oxidase 
activity, 2) N-acetyltransferase activity, 3) sulphate conjugation, and 4) p-alanine 
conjugation (from Evans, 1985). 
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route of octopamine metabolism in the lobster (Kennedy, 1977; Kennedy, 1978). 4) 
N-methylation of octopamine by phenylethanolamine-n-methyl-transferase (PNMT) 
(Fig. 2) to synephrine (N-methyl octopamine) and ~-hydroxylation of octopamine to 
norepinephrine is another minor route of octopamine metabolism (Saavedra, 1989; 
Axelrod and Saavedra, 1977). 
Function of octopamine 
It has been well established that octopamine functions as a neurotransmitter, 
a neuromodulator, and a neurohormone in the invertebrate (Axelrod and Saavedra, 
1977; Orchard, 1982; Evans, 1985; Bicker and Randolf, 1989; Saavedra, 1989). 
Octopamine is a neurotransmitter in the firefly lantern and controls the time of 
the light flashes (Carlson, 1969) and it also controls the release of hyperlipemic 
hormone (increase the level of lipid) in the hemolymph during the flight from 
Corpoora Cardiaca (Orchard, 1982; Evans, 1985). Modulation of the myogenic 
rhythm and potentiation of neuromuscular transmission are examples of the 
neuromodulator function of octopamine (Orchard, 1982; Evans, 1985). Octopamine 
is released during the initial period of flight and under stress conditions in insect 
hemolymph, suggesting a role of octopamine as a neurohormone (Evans, 1985). 
The physiological role of octopamine in mammals is not clear (Harmar and 
Horn, 1976; Saavedra, 1989). However, octopamine is present in high concentration 
in mammals experiencing pathological conditions such as phenylketonuria, hepatic 
pathology, depression, aggression, stress, migraine, epilepsy, Parkinson's disease, 
and hypertension, suggesting that octopamine may play a pathophysiological role in 
these conditions (Axelrod and Saavedra, 1977; Saavedra, 1989). 
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Octopamine receptors 
Octopamine receptors have been studied in both neural (Nathanson and 
Greengard, 1973; Evans and O'shea, 1978; Roder and Grweecke, 1990; Roder, 
1995) and non-neural tissues in invertebrates (Evans, 1981; Evans, 1985). There 
are three classes of octopamine receptors in the locust extensor-tibiae 
neuromuscular (Evans, 1981). Octopamine receptors are classified as 1) 
octopamine receptor 1 (OAR1), 2) presynaptic octopamine receptor 2A (OAR2A), and 
3) postsynaptic octopamine receptor 28 (OAR2s). 
OAR1 can be distinguished from OAR2 on the basis of the affinity for different 
agonists and antagonists. Chlorpromazine and yohimbine are better antagonists 
than metoclopramide for OAR1, while the opposite is true for OAR2. Also clonidine is 
a much better agonist than naphazoline for OAR1, while the converse is true for 
OAR2 (Evans, 1981; Evans, 1985). In similar pattern, OAR2A can be distinguished 
from OAR28 . Cyproheptadine, mianserin, and metoclopramide are better 
antagonists for OAR2A than OAR2s. On the other hand, chlorpromazine is a better 
antagonist for OAR2B. Naphazoline is a better agonist than tolazoline for OAR2A, 
while the converse is true for OAR2s (Evans, 1981; Evans, 1985). 
Octopamine receptors have similar pharmacological features to a-adrenergic 
receptors (ARs) in vertebrates (Evans, 1981; Evans, 1985), since they can be 
blocked by a-AR antagonists such as phentolamine but not by p-AR antagonists 
such as propranolol (Evans, 1985). Clonidine and tolazoline (a-AR agonists) have 
agonistic activity on octopamine receptors while isoproterenol (a P- AR agonist) does 
not have this activity (Evans, 1985). Octopamine receptors can be distinguished 
10 
from ARs in terms of amine specificity. Octopamine receptors prefer mono-phenolic 
amines with a single hydroxyl group on the aromatic ring, while ARs prefer two 
hydroxyls on the ring (Evans, 1985). 
Mechanism of action of octopamine 
Octopamine mediates it's effect through activation of adenylate cyclase 
(Evans, 1985) via stimulation of a special octopamine-sensitive adenylate cyclase 
(Nathanson , 1979; Evans, 1980; Saavedra, 1989) in both neural and non-neural 
tissues, which results in an increase in the formation of cyclic AMP. The 
octopamine-sensitive adenylate cyclase in the invertebrate has been demonstrated 
to be the site of action for pesticides (Nathanson, 1979; Saavedra, 1989). 
Octopamine receptors are thought to be an ideal target for specific insecticides such 
as the formamidine pesticides: chlordimeform (COM), N-dimethylchlordimeform 
(DCDM), and amitraz (Evans, 1985; Roder, 1995). 
Toxic effects of amitraz and mechanisms of action 
Earlier studies suggested that toxic effects of formamidines in mammals 
include: persistent activation of monoamines by inhibiting monoamine oxidase (Aziz 
and Knoweles, 1973; Benzent and Knowles, 1976; Matsumura and Beeman, 1976); 
inhibition of oxidative phosphorylation (Abo-Khatwa and Hollingworth , 1974); 
anticholinergic activity (Wang et al. , 1975); local anesthesia (Lund et al., 1978; 
Gilbert and Mack, 1989); and antihistaminic activity (Pass and Seawright, 1982; 
Pass and Mogg, 1991). 
Over sixteen cases of amitraz toxicity in humans have been reported (FDA 
Veterinarian, 1989; Ros and Aken, 1994; Kennel et al. , 1996; Jorens et al. ; 1997; 
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Aydin et al., 1997). The clinical signs include hyperglycemia, bradycardia, 
hypotension, miosis, headache, nausea, drowsiness, vomiting, polyuria, rash, 
stiffness, swelling, and coma. The toxic effects of amitraz in animals include 
hyperglycemia, central nervous system (CNS) depression, bradycardia, 
hypertension, polyuria, mydriasis, vomiting, delayed gastrointestinal transit, bloat, 
and colic (Dobozy, 1990). 
While most of the toxic signs resulting from exposure to amitraz are similar 
between humans and animals, hypotension was reported in humans, while both 
hypertension (Hsu et al., 1986; Cullen and Reynoldson, 1987; Cullen and 
Reynoldson, 1988) and hypotension (Pascoe and Reynoldson, 1986; Reynoldson 
and Cullen, 1996) were reported in animals. The hypertensive effect of amitraz may 
be attributed to activation of a-ARs in the vascular bed, while the hypotensive and 
bradycardic effects could be attributed to a2-AR-mediated decreases in sympathetic 
outflow from the CNS and increases in vagal tone (Clark and Hall, 1969; Schmitt et 
al., 1970; Antonaccio et al. , 1973). The decreased sympathetic outflow is believed 
to originate from both pre- and postsynaptic a2-ARs in the pontomedullary region of 
the CNS (McCall et al., 1983; Van Zwieten and Timmermans, 1983). Activation of 
the presynaptic a2-ARs located on the adrenergic terminals also inhibits peripheral 
adrenergic neurotransmission (Langer, 1980; Starke, 1980; De Jonge et al. , 1980). 
The increase of vagal tone by a2-agonists may be due to a facilitation of the 
baroreceptor reflex (Hucht et al. , 1981; Kitagawa and Walland, 1982). Miosis, 
reported in humans could be attributed to a decrease in the sympathetic outflow, 
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while mydriasis, reported in animals could be attributed to a decrease in the 
parasympathetic outflow. 
The toxic effects of amitraz resemble those induced by the a2-AR agonists, 
xylazine and clonidine (Hsu and Kakuk, 1984). In addition, the a2-AR antagonists 
such as yohimbine, but not the a1-AR antagonists, attenuate or block several of the 
effects of amitraz such as: CNS depression (Hsu and Hopper, 1986; Schaffer et al., 
1990), bradycardia (Hsu and Kakuk, 1984; Hsu and McNeel, 1986; Hsu et al., 1986; 
Schaffer et al., 1990; Cullen and Reynoldson, 1987), hypertension (Hsu et al., 1986; 
Cullen and Reynoldson, 1987), mydriasis (Hsu and Kakuk, 1984), delayed 
gastrointestinal transit (Hsu and Lu, 1984; Hsu and McNeel, 1985; Robert and 
Argenzio, 1986; Hsu et al., 1987 ), and glucose intolerance (Smith et al., 1990). 
Death in rats caused by intraperitoneal injections of amitraz is reduced by 
yohimbine (Moser and McPhail, 1985). Amitraz causes a dose-dependent inhibition 
of [3H]clonidine and [3H]yohimbine binding to a2-AR in mouse brain (Costa et al., 
1989a) and rat brain (Costa et al., 1989b). Amitraz inhibits epinephrine-induced 
canine platelet aggregation in a dose-dependent manner, and also inhibits 
[3H]yohimbine binding to a2-ARs (Koeiman and Hsu, 1991 ). These findings suggest 
that the a2-ARs mediate a number of the toxic effects of amitraz and that a2-AR 
antagonists have the ability to block these effects. 
Amitraz has been shown to decrease hepatic glutathione concentration by 
activating hepatic a2-ARs similar to epinephrine and clonidine (Costa et al., 1991 ). 
Neither amitraz nor its metabolites are mutagens (Tudek et al., 1988). 
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Characterization of a-adrenergic receptors 
Classification of ARs 
The ARs were initially classified as a- and P-ARs subtypes, based on their 
pharmacological response to five catecholamines on eight different physiological 
functions (Ahlquist, 1948). Subsequently, the p-ARs were divided into p1 and p2 
subtypes based on their affinity for agonists (Lands et al., 1967), and selective 
antagonists and by binding studies (Minneman et al., 1979). Later, a third P-AR was 
isolated and designated as p3-AR (Emorine et al, 1989). a-ARs were first classified 
into a1 and a2 subtypes (Delbarre and Schmitt, 1973). Based on their anatomical 
location, a-ARs were subclassified as presynaptic (prejunctional) a-ARs and 
postsynaptic (postjuctional) a-ARs (Dubocovich and Langer, 1974). Langer (1974) 
suggested that the postsynaptic a-ARs be referred to a1, while the presynaptic a-
ARs be referred to a2 . Subsequently, a-ARs were classified according to their 
physiological functions namely that a1-ARs mediate excitatory effects, while a 2-ARs 
mediate inhibitory effects (Berthelsen and Pettinger, 1977). 
Both prazosin and yohimbine antagonize norepinephrine-induced presser 
responses (Drew and Whiting, 1979) indicating that both a1-ARs and a 2-ARs 
mediate postsynaptic excitatory responses. Therefore, the a-ARs subclassification 
based on anatomical location or physiological function does not appear to be 
sufficient. Pharmacological classification in terms of the affinities of agonists and 
antagonists was proposed as a better method by which to subclassify a-ARs 
(Starke, 1981; Ruffolo et al., 1991). The a1-ARs are activated by methoxamine, 
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cirazoline, and phenylephrine and antagonized by prazosin and WB 4101. The a2-
ARs are activated by clonidine, xylazine, medetomidine and UK 14304 and 
antagonized by yohimbine, rauwolsin, and idazoxan. 
a1-ARs heterogeneity 
Based on pharmacological characteristics and molecular cloning the a1-ARs 
have been further classified into three subtypes: a1A-, a 18-, a10-ARs (Table 1 ). The 
a1A-ARs are characterized by a selective agonistic activity for oxymetazoline and 
cirazoline (Horie et al., 1995), and a selective antagonistic activity for 5-
methylurapidil and (+)-Niguldipine (Gross et al., 1988; Boer et al., 1989). The gene 
for a1A-ARs has been cloned from the bovine brain complementary DNA (Schwinn et 
al., 1990). 
The a 18-ARs have no selective agonists or antagonists (Table 1). However, 
a 18-ARs have a low affinity for WB 4101 , 5-methylurapidil , and phentolamine 
(Cotecchia et al., 1988; Lomasney et al., 1991). The gene for a 18-ARs has been 
cloned from hamster complementary DNA (Cotecchia et al., 1988). 
A third distinct subtype designated as a10-AR was cloned from rat brain 
complementary DNA (Lomasney et al., 1991; Perez et al., 1991). This receptor has 
no selective agonists or antagonists. 
arARs heterogeneity 
Based on pharmacological characteristics and molecular cloning a2-ARs have 
been subclassified into four subtypes: a2A-, a2s-, a2c-, a20-ARs (Bylund, 1992; 
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Table 1: Subtypes of a-Adrenergic Receptors 
a-ARs Gene Located Selective Selective Tissue in human 
subtype chromosome # agonists antagonists localization 
a1A 8 Oxymetazoline 5- Heart, liver, 
, cirazoline Methylurapidil, cerebellum, 
(+)-Niguldipine cerebral 
cortex, 
prostate, lung, 
vas deferens 
a10 5 None WB 4101 (low Kidney, 
affinity) spleen, aorta, 
lung, cerebral 
cortex 
a10 20 None None Aorta, cerebral 
cortex, 
prostate, 
hippocampus 
a2A * 10 Oxymetazoline BRL 44408 Platelet, 
cerebral 
cortex, locus 
cervleus, 
spinal cord 
a2B 2 None Prazosin, Liver, kidney 
ARC-239, BRL 
42992 
a2c 4 None Prazosin, Cerebral 
ARC- 239, cortex 
Rauwolsine, 
WB 4101 , 
BAM 1303 
* a2A and aw are species orthologs, e.g. human and pigs have a2A whereas rats and 
cattle have aw. The aw receptors have no selective agonists or antagonists. 
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Bylund et al., 1994). The a2A-ARs, are characterized by a high affinity for 
oxymetazoline and BRL 44408 (Table 1) and low affinity for prazosin and ARC-239, 
are expressed in human platelets and HT29 (a human adenocarcinoma cell line) 
(Bylund et al., 1988). The gene for the a2A-ARs has been cloned from human 
(KobilKa et al., 1987), pig (Guyer et al., 1990), and guinea pig (Svensson et al. , 
1996). 
The a2s-ARs are found in neonatal rat lung and the NG 108 cell line 
(neurobalstoma x glioma hybrid cell line) (Bylund et al. , 1988). The gene has been 
cloned from human (Lomasney et al., 1990; Weinshank et al. , 1990), rat (Zeng et al., 
1990), mouse (Chruscinski et al. , 1992) and guinea pig (Sevnsson et al., 1996). The 
a28-ARs have no selective agonists (Table 1), but they do have a relatively high 
affinity for prazosin, BRL 42992, and ARC-239, and low affinity for oxymetazoline 
(Bylund et al., 1988). 
The third a2-AR subtype, a2c-AR, has been identified from an opossum 
kidney-derived cell line (OK cells) (Murphy and Bylund, 1988). This receptor 
subtype has no selective agonists (Table 1 ), and has similar characteristics to a28-
AR (e.g. high affinity of prazosin), but the affinity is intermediate between a2A- and 
a2s-ARs (Murphy and Bylund, 1988). a2c-ARs are distinguished from a28-ARs by 
their higher affinity for the antagonists rauwolscine, WB 4101 , and BAM 1303 
(Blaxall et al., 1991). The gene for a2c-ARs has been cloned from human (Regan et 
al. , 1988), rat (Lanier et al. , 1991 ), mouse (Link et al. , 1992), and guinea pig 
(Svensson et al. , 1996). 
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The a20-ARs have been found in bovine pineal gland (Simonneaux et al., 
1991), rat submaxillary glands (Michel et al., 1989), and the p-cell tumor-derived cell 
line (RINm5F) (Remaury and Paris, 1992). SK&F 104078, an a2-antagonist, blocks 
a2A-,a2s-, a2c-ARs, but not a20-AR (Bylund and Iversen, 1990). a20-ARs have no 
selective agonists or antagonists, and the gene has been cloned from the rat (Lanier 
et al., 1991) and mouse (Link et al., 1992). a2A- and a20-ARs are species orthologs 
(O'rourke et al , 1994), which means that a species may have either a2A or a20, but 
not both. Humans and pigs have a2A-ARs, whereas rats and cattle have a20-ARs 
(O'rourke et al , 1994). 
Signal transduction of a1-ARs 
The a 1-ARs are coupled to a variety of regulatory systems (Table 2). These 
include: 
1) The mobilization of intracellular Ca2+ from the endoplasmic reticulum. The 
activation of phospholipase C (PLC) through the Gq family leads to hydrolysis of 
membrane-bound polyphosphoinositides, which results in the generation of 
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) (Lefowitz et al., 1996; 
Piascik et al. , 1996). IP3 stimulates Ca2+ release from the endoplasmic reticulum, 
whereas DAG activates protein kinase C (PKC) that can phosphorylate many 
regulatory proteins (Berridge, 1993). 
2) The stimulation of phospholipase A2 (PLA2), which leads to the release of free 
arachidonate to produce prostaglandins and leukotrienes via cyclooxygenase and 
lipoxygenase pathways, respectively. 
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3) The stimulation of phospholipase D (PLO), that leads to hydrolysis of 
phosphatidylcholine and yields phosphatidic acid (PA). PA acts as a second 
messenger by releasing Ca2+ from the endoplasmic reticulum. It is also metabolized 
to DAG (Lefowitz et al., 1996). 
Signal transduction of a2-ARs 
The a2-ARs couple to a variety of effectors (Table 2) . Activation of a2-ARs 
leads to: 
1) The inhibition of adenylate cyclase activity and the reduction of cyclic AMP 
formation in different target cells including human platelets (Mills, 1975), 
neuroblastoma x glioma hybrid cells (Sabol and Nirenberg, 1979), rat renal cortex 
(Woodcock and Johnston, 1982), porcine thyroid (Muraki et al, 1984 ), and rat 
pancreatic islets (Yamazaki et al, 1982). 
2) The activation of G-protein-gated K+ channels which leads to membrane 
hyperpolarization (Egan et al. , 1983; Morita and North, 1981; Lefowitz et al.,1996). 
3) The inhibition of voltage-gated Ca2+ Channels (Horn and McAffee, 1980; Holz 
et al., 1986; Lefowitz et al.,1996). 
4) Other messenger systems linked to the a2-ARs: 
a) The acceleration of Na+/H+ exchange (Sweatt et al., 1985), resulting in an 
increase in intracellular pH, and Na+ concentration. 
b) The stimulation of PLA2 (Sweatt et al., 1986). 
c) The stimulation of PLO (MacNulty et al. 1990). 
d) The stimulation of PLC (Cotecchia et al. , 1990). 
19 
The activation of these pathways by the a2-ARs is pertussis-toxin sensitive, 
suggesting that GTP-binding proteins of the G/G0 subfamily are responsible for 
eliciting these effects (Limbird, 1988; Piascik et al., 1996). All four subtypes of a2-
ARs have no difference or selectivity in signal transduction mechanisms (Bylund et 
al., 1994). 
Role of aradrenergic receptors on the endocrine pancreas 
Effect on insulin secretion 
The endocrine pancreas is innervated by the sympathetic nervous system 
(Smith and Porte, 1976), which plays an important role in the regulation of the 
secretion of pancreatic hormones through the release of catecholamines. 
Stimulation of splanchnic nerves (Porte et al., 1973), and the ventromedial 
hypothalamus (Forhman and Bernard is, 1971) leads to activation of the sympathetic 
nervous system, thereby decreasing insulin secretion (Porte et al., 1966). 
The a2-ARs are responsible for the inhibition of glucose-stimulated insulin 
secretion (Nakaki et al., 1983; Ismail et al., 1983; Skoglund et al., 1986; Schuit and 
Pipeleers, 1986; Hirose et al, 1997). Nonselective a-AR agonists such as 
epinephrine and norepinphrine, and selective a2-AR agonists such as clonidine, 
xylazine, medetomidine, oxymetazoline, and UK 14.304 inhibit insulin secretion 
(Ismail et al., 1983; Angel et al., 1988; Niddam et al., 1990; Angel et al., 1990; Chen 
and Hsu, 1994). The a2-AR antagonists but not the a 1-AR antagonists counteract 
the inhibitory effect on insulin secretion. The a2-AR agonists cause temporary 
diabetes mellitus in cattle (Hsu and Hummel, 1981), whereas a2-AR antagonists 
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improve insulin secretion and glucose disposal in type II diabetic patients (Kashiwagi 
et al., 1986; Ortiz-Alonso et al., 1991). 
It is well established that the a2-ARs mediate the inhibition of insulin secretion 
from p-cells of the pancreas. One possible mechanism for this effect is through the 
inhibition of adenylate cyclase, an action mediated by a PTX-sensitive G-protein 
(Chen and Hsu, 1994; Horise et al, 1997). However, it is still not known which a2-AR 
subtypes mediate this inhibition. Only two published studies have dealt with the 
characterization of the a2-AR subtype that mediates the inhibition of insulin secretion 
(Angel et al, 1990; Hirose et al, 1993a). These authors suggested that a2KAR is 
responsible for the inhibition of insulin secretion. However, in both studies 
oxymetazoline was used as an a2-AR agonist, despite the fact that oxymetazoline 
has potent a1-AR agonistic activity (Garicia et al., 1995). In the first study a specific 
a2-AR antagonist was not used since WB 4101 antagonizes both a2A- and a2c-ARs 
(Hieble and Ruffolo, 1995). In the second study idazoxan was used as a selective 
a2A-antagonist and yohimbine as a nonselective antagonist, while it is known that 
idazoxan antagonizes aw- more than a2A-ARs, and yohimbine antagonizes a2A-
more than aw-ARs (Satoh and Takayanagi, 1992). In addition, rodents have aw-
ARs, but not a2A-ARs since a2A and aw are species orthologs (O'Rourke et al, 
1994). Therefore, it is likely that aw-ARs are the receptors that mediate the 
inhibition of insulin in rodents. 
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Effect on glucagon secretion 
The a 2-AR agonists such as oxymetazoline and clonidine stimulate glucagon 
secretion from a-cells of the pancreatic islet in the rat. The a2-AR antagonists but not 
the a 1-AR antagonists counteract the stimulatory effect on glucagon secretion 
(Gotch et al. , 1988; Horise et al. , 1993a; 1993b; 1993c). 
It is possible that the effect of the az-AR agonists on glucagon secretion is 
through a direct stimulation of the pancreatic a-cells or indirectly through an 
inhibition of insulin secretion, since it is known that insulin inhibits glucagon secretion 
(Waeber et al., 1997). Several studies suggested that a2-AR agonist-induced 
glucagon secretion is mediated mainly through the direct stimulation of a-cells 
(Tominaga et al., 1987; Hirose et al , 1993c). Glucagon secretion was induced by az-
AR agonists in the absence of any changes in insulin secretion (Hirose et al, 1993c). 
However, this study did not demonstrate the inhibitory effect of az-AR agonists on 
insulin secretion due to the very low basal insulin secretion rate. The very low 
insulin concentration might be due to an insensitive insulin assay that could not 
detect changes in low basal concentrations of insulin. In another study, increases in 
glucagon secretion induced by norepinephrine were still present after the destruction 
of pancreatic p-cells by streptozocin in rats (Tominaga et al., 1987; Hirose et al; 
1993c). However, norepinephrine was used rather than a selective az-AR agonist 
and p-antatgonist was not used to exclude the p-adrenergic effect. It is likely that 
glucagon secretion is mediated mainly through the direct stimulation of a-cells and to 
a lesser extent through the indirect inhibition of insulin secretion. 
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Effect of amitraz on glucose metabolism and endocrine secretion 
The effects of amitraz on glucose metabolism and endocrine secretion were 
first noted in dogs through the clinical use of this pesticide. Topical administration of 
amitraz to dogs at concentrations of~ 227 ppm of an aqueous suspension caused 
hyperglycemia (Hsu and Schaffer, 1988; and Dobozy, 1990) and hypoinsulinemia 
(Hsu and Schaffer, 1988). Normal dogs dipped in an aqueous suspension of 555 
ppm (twice the recommended dose) showed no increase in insulin release following 
IV injection of glucose (0.6 g/kg) that was given 4 h after amitraz application (Hsu 
and Schaffer, 1988). It is not known how much cutaneous absorption of amitraz 
takes place through dipping; however, because amitraz is highly lipid soluble, a 
significant amount of amitraz is expected to be absorbed into the body. 
Oral administration of amitraz (100 mg/kg) increases plasma glucose 
concentration and decreases insulin secretion in dogs, which were antagonized by 
atipamezole, an a 2-AR antagonist (50µg/kg, IM) (Hugnet et al., 1996). Intravenous 
administration of amitraz into rats at dosages of 0.1, 0.3, and 1 mg/kg followed by IV 
injection of glucose (1 g/kg) caused a dose-dependent inhibition of plasma insulin 
and glucose intolerance (Smith et al., 1990). Intravenous administration of amitraz 
at 1 mg/kg completely suppressed the insulin secretion induced by IV glucose 
(Smith et al., 1990). In addition, amitraz and its active metabolite, BTS 27271, 
inhibited 3-isobutyl-1-methyl xanthine (IBMX) (a phosphdiesterase inhibitor)-
stimulated insulin secretion from a ~-cell line, RINm5F (Chen and Hsu, 1994). 
Amitraz, BTS 27271, and medetomidine, an a2-AR agonist, inhibited IBMX-induced 
increases in intracellular cyclic AMP concentrations (Chen and Hsu, 1994). In 
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pertussis toxin (PTX)-pretreated cells, neither amitraz nor BTS 27271 attenuated the 
IBMX-induced increase in insulin secretion (Chen and Hsu, 1994). These results 
suggest that amitraz and its active metabolite BTS 27271 induce hyperglycemia 
through the inhibition of insulin secretion, which is mediated by a2-ARs. One 
possible mechanism for this effect is through the inhibition of adenylate cyclase, an 
action mediated by PTX-sensitive G-proteins (Chen and Hsu, 1994). 
Since hyperglycemia is found in human cases of amitraz poisoning, the 
exposure to this pesticide would be expected to pose a great hazard to patients with 
type II diabetes, who already have impaired insulin secretion and/or utilization. 
There are at least 14 million people with type II diabetes in the U.S.A. Exposure of 
these individuals to amitraz and its active metabolite might reduce their insulin 
secretion and further hamper glucose metabolism. The a2-AR agonists cause a 
greater suppression of insulin secretion from human patients with type II diabetes 
than from normal subjects (Okada et al., 1986; and Koev et al., 1989). 
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EFFECTS OF AMITRAZ ON INSULIN AND GLUCAGON 
SECRETION 
Introduction 
Amitraz (N'-[2,4-dimethylphenyl]-N-[(2,4-dimethylphenyl)imino]-N-
methylmethanimidamide) is a formamidne insecticide/acaricide used to treat mange 
in animals (Farmer and Seawright, 1980) and kill arthropods in agronomy and 
horticulture practice (Farm Chemicals Handbook, 1996). The insecticide/acaricide 
actions of amitraz may be mediated by octopamine receptors (Evans, 1980; Singh et 
al., 1981, Hashemzadeh et al., 1985; Roder, 1995). 
Amitraz is rapidly absorbed, distributed, metabolized, and eliminated primarily 
via urine when administered orally to mammals. The degradation products present 
in the urine include N'-[2,4-dimethylphenyl]-N-methylformamidine (BTS 27271 ), 2,4-
dimethylformanilide, 2,4-dimethylformanilide, 2,4-dimethylaniline, 4-formamido-3-
methylbenzoic acid, 4-amino-3-methylbenzoic acid, and several unknowns (Knowles 
and Benezet, 1981 ). BTS 27271, one of the metabolites of amitraz, has been found 
to be more potent than amitraz with regard to its miticidal activity (Schuntner and 
Thompson, 1978) and mammalian toxicity (Pass and Mogg, 1991; Chen and Hsu, 
1994). 
Over sixteen cases of amitraz toxicity in humans have been reported (FDA 
Veterinarian, 1989; Ros and Aken, 1994; Kennel et al., 1996; Jorens et al.; 1997; 
and Aydin et al., 1997). Symptoms include hyperglycemia, bradycardia, hypotension, 
25 
miosis, headache, nausea, drowsiness, vomiting , polyuria, rash, stiffness, swelling, 
and coma. The toxic effects of amitraz in animals include hyperglycemia, central 
nervous system (CNS) depression, bradycardia, hypertension, polyuria, mydriasis, 
vomiting, delayed gastrointestinal transit, bloat, and colic (Dobozy, 1990). The toxic 
effects of amitraz resemble those induced by the a2-AR agonists, xylazine and 
clonidine (Hsu and Kakuk, 1984). In addition, a2-AR antagonists such as yohimbine, 
but not the a1-AR antagonists, attenuate or block several of the effects of amitraz 
such as: CNS depression (Hsu and Hopper, 1986; Schaffer et al., 1990), 
bradycardia (Hsu and Kakuk, 1984; Hsu and McNeel, 1986; Hsu et al., 1986; 
Schaffer et al., 1990; Reynoldson and Cullen, 1987), hypertension (Hsu et al., 1986; 
Reynoldson and Cullen, 1987), mydriasis (Hsu and Kakuk, 1984), delayed 
gastrointestinal transit (Hsu and Lu, 1984; Hsu and McNeel, 1985; Robert and 
Argenzio, 1986; Hsu et al., 1987 ), and glucose intolerance (Smith et al., 1990). 
Amitraz causes a dose-dependent inhibition of [3H]clonidine and [3H]yohimbine 
binding to a2-AR mouse brain (Costa et al. , 1990) and rat brain(Costa et al. , 1988). 
These findings suggest that the a2-ARs mediate a number of the effects of amitraz 
and that the a2-AR antagonists have the ability to block these effects. 
Amitraz causes hyperglycemia and hypoinsulinemia when used topically (Hsu 
and Schaffer, 1988), orally (Hug net et al. , 1996), and intravenously (Smith et al. , 
1990). These effects of amitraz are similar to those induced by the a2-AR agonists. 
In addition, yohimbine, an a2-AR antagonist, antagonized the effect of amitraz on 
insulin secretion, whereas prazosin, an a1-AR antagonist, did not (Smith et al. , 1990; 
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Chen and Hsu, 1994). Amitraz and its active metabolite, BTS 27271, inhibits 
intracellular cyclic AMP concentration and insulin secretion from a p-cell line, 
RINm5F, (Chen and Hsu, 1994). Pretreatment of RINm5F cells with pertussis toxin 
(PTX) antagonized the effect of amitraz and BTS 27271 on insulin secretion. These 
results suggest that amitraz and its active metabolite BTS 27271 induce 
hyperglycemia through inhibition of insulin secretion, which is mediated by a2-ARs. 
One possible mechanism for this effect is through the inhibition of adenylate cyclase, 
an action mediated by PTX-sensitive G-proteins (Chen and Hsu, 1994). 
The a2-AR agonists such as oxymetazoline and clonidine stimulate glucagon 
secretion from a-cells of the pancreatic islet in the rat. The a2-AR antagonists but 
not the a1-AR antagonists counteract the stimulatory effect on glucagon secretion 
(Gotoh et al., 1988; Hirose et al., 1993a; 1993b; 1993c). 
Since previous studies have not investigated the direct effect of amitraz and 
its active metabolite BTS 27271 on the secretion of the insulin and glucagon from 
the pancreas, the present study was designed to address this question and in 
addition, to characterize the a-ARs that mediate the effect of amitraz on insulin 
secretion from the pancreas. 
Materials and Methods 
Male Sprague-Dawley rats (300-400 g) were used. The rats were 
anesthetized with sodium pentobarbital (60 mg/kg, ip), maintained at 37C 0 on a hot 
plate, and were kept alive during the experiment. Pancreatic perfusion was 
performed as previously described (Yang and Hsu, 1995). After cannulation of the 
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celiac artery, the rat pancreas was immediately perfused with Krebs-Ringer 
Bicarbonate (KRB) solution supplemented with 20 mM N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid, 5.5 mM glucose, and 0.2% bovine serum albumin as a 
basal medium. The KRB was maintained at pH 7.4 and continuously aerated with 
95% 02 - 5% C02. 
Experimental design 
The first 15-20 min of perfusion was considered as an equilibration period. 
Subsequently, the effluent fluid was collected every min from the cannula in the 
portal vein. The flow was maintained at 1 ml/min . In experiment 1, after a baseline 
period of 10-min, the medium containing amitraz (10-8 , 10-7, 10-6 , or 10-5 M) was 
administered for 10-min, and was followed by a washout period during which the 
basal medium was administered for 10-min. In experiment 2, after a baseline period 
of 10-min, the medium containing BTS 27271 (10-9, 10-8, 10-7, 10-6, or 10-5 M), the 
active metabolite of amitraz, was administered for 10 min, and was followed by a 
washout period during which the basal medium was administered for 10-min. In 
experiment 3, the pancreas was pretreated for 10-min with a medium containing 
either the a-AR antagonist idazoxan (10-8, 10-7, or 10-6 M), or prazosin (10-6 M). This 
was followed by the medium containing amitraz (10-6 M) and idazoxan or prazosin 
for 10-min, and the basal medium for another 10-min for the washout period. In all 
experiments, 1 mM arginine was administrated at the end of experiment for 10-min 
to stimulate both insulin and glucagon secretion, in order to confirm that the tissue 
retained the normal secretory capacity under the experimental conditions. The 
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effluent fluids were kept at 4°C and subsequently assayed within 6 h for insulin and 
glucagon using radioimmunoassy (RIA) . 
Drugs 
The following drugs were used: amitraz (Agr Evo, Pikeville , NC), BTS 27271 
HCI (Nor-Am Chemical, Wilmington, DE) , idazoxan (Reckitt & Colman 
Pharmaceutical, England), and prazosin HCI (Pfizer, Groton , CT) . All drugs were 
dissolved in distilled H20 except amitraz, which was dissolved in dimethyl sulfoxide 
(DMSO) to make stock solution of 5x10-3 M. These solutions were further diluted 
with the KRB (basal medium) to attain the appropriate concentrations. Control 
experiments were performed following the same protocol except that KRB was used 
in place of the drugs. 
Data expression and statistical analysis 
The effluent concentrations of insulin and glucagon were expressed as a 
percentage of the baseline level (mean of 10 baseline values) in means± SE. The 
area under the curve (treatment period area, washout period area, and arginine 
period area) was calculated using a scanning program (Sigma Scan ; Jandel, Corte 
Madera, CA). Data were analyzed using the SAS Proc General Linear Means 
(GLM) procedure. The factors were drugs (2 levels), dose (5 levels), and area (3 
levels). The general design is a split-plot factorial design with repeated measures. 
Individual mean comparisons were calculated using the F test. The significance 
level was set at P < 0.05. 
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Results 
Effects of amitraz on insulin secretion 
Insulin secretion remained constant during the first 30-min in the control 
group receiving 5.5 mM glucose only. Administration of 1 mM arginine in the control 
group increased insulin secretion by - 200% of the baseline level at the end of the 
experiment (Fig. 4) . Amitraz caused a concentration-dependent inhibition of insulin 
secretion. Amitraz (10-8 , 10-7 , 10-6 , or 10-5 M) significantly inhibited insulin secretion, 
and reached a maximal inhibition of 33%, 47%, 60%, and 77% of the baseline level, 
respectively (Figs. 4 and 5). The effluent concentrations of insulin remained low 
during the 10-min washout period in all the groups, although it was expected that the 
effluent concentrations of insulin would return to baseline level. Amitraz (~ 10-7 M) 
significantly inhibited arginine-induced insulin secretion (Figs. 4 and 5). 
By calculating the area under the curve for the amitraz treatment and by using 
the corresponding area of the control groups as 100%, amitraz (10-8, 10-7, 1 o-6, or 
10-5 M) significantly inhibited insulin secretion in a concentration-dependent manner 
(Fig. 6). Also by calculating the area under the curve for the arginine treatment and 
by using the corresponding area of the control groups as 100%, amitraz (10-7, 10-6, 
or 10-5 M) significantly inhibited arginine-induced insulin secretion (Fig. 7). 
Effects of amitraz on glucagon secretion 
The effluent concentrations of glucagon remained constant in the control 
group receiving 5.5 mM glucose only. Administration of 1 mM arginine into the 
control group increased glucagon secretion with a peak of - 470% of the baseline 
level (Fig. 8). Amitraz (10-8 , 10-7 , or 10-6 M) did not cause any significant increases 
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Fig. 4. The effects of 10-8 M and 10-7 M amitraz (A) on insulin secretion from the 
perfused rat pancreas. After a baseline period of 10 min, amitraz (shown in the 
heavy line) was given for 10 min, followed by 10 min of the washout period. At the 
end of the experiment, 1 mM arginine (shown in the heavy line) was given for 10 
min. Values are shown as mean± SE (n=4). 
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Fig. 5. The effects of 10-6 M and 10-5 M amitraz (A) on insulin secretion from the 
perfused rat pancreas. After a baseline period of 10 min, amitraz (shown in the 
heavy line) was given for 10 min, followed by 10 min of the washout period. At the 
end of the experiment, 1 mM arginine (shown in the heavy line) was given for 10 
min. Values are shown as mean ± SE (n=5). 
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Fig. 8. The effects of 10-8 M and 10-7 M amitraz (A) on glucagon secretion from the 
perfused rat pancreas. After a baseline period of 10 min, amitraz (shown in the 
heavy line) was given for 10 min, followed by 10 min of the washout period. At the 
end of the experiment, 1 mM arginine (shown in the heavy line) was given for 10 
min. Values are shown as mean ± SE (n=4 ). 
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In glucagon secretion during the treatment and the washout periods (Figs. 8, and 9). 
However, Amitraz (10-5 M) significantly increased glucagon secretion with a peak of 
265% of the baseline level (Fig. 9). The effluent concentrations of glucagon level 
remained high during the 10-min washout period (Fig. 9). Amitraz (~ 10-7 M) 
significantly enhanced arginine-induced glucagon secretion (Figs. 8 and 9). 
By calculating the area under the curve for the arginine treatment and by 
using the corresponding area of the control groups as 100%, Amitraz (10-7, 10-6 , or 
10-5 M) significantly enhanced arginine-induced glucagon secretion in a 
concentration-dependent manner (Fig . 10). 
Effects of BTS 27271 on insulin secretion 
In a pattern similar to amitraz, BTS 27271, the active metabolite of amitraz, 
caused a concentration-dependent inhibition of insulin secretion. The BTS 27271 
(10-9 M) did not cause any significant inhibition of insulin secretion (Fig . 11 ). 
However, BTS 27271 administrated at 10-8, 10-7, 10-6, or 10-5 M significantly inhibited 
insulin secretion, with a maximal inhibition of 34%, 52%, 72%, and 85% of the 
baseline level, respectively (Figs. 12 and 13). The effluent concentrations of insulin 
remained low in all groups during the 10-min washout period. The BTS 27271 (~ 10-
7 M) caused a significant inhibition of arginine-induced insulin secretion (Figs. 12 and 
13). 
By calculating the area under the curve for the BTS 27271 treatment and by 
using the corresponding area of the control groups as 100%, BTS 27271 (10-8 , 10-7 , 
10-6 , or 10-5 M) significantly inhibited insulin secretion in a concentration-dependent 
manner (Fig. 14). Also by calculating the area under the curve for the arginine 
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Fig. 9. The effects of 10-6 M and 10-5 M amitraz (A) on glucagon secretion from the 
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min. Values are shown as mean± SE (n=5). 
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for 10 min, followed by 10 min of the washout period. At the end of experiment, 1 
mM arginine was given for 10 min (shown in the heavy line). Values are shown as 
mean± SE (n=3-4). 
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Fig. 12. The effects of 10-8 Mand 10-7 M BTS 27271 on insulin secretion from the 
perfused rat pancreas. After baseline period of 10 min, BTS (shown in the heavy 
line) was given for 10 min, followed by 10 min of the washout period. At the end of 
experiment, 1 mM arginine was given for 10 min (shown in the heavy line). Values 
are shown as mean ± SE (n=3-4 ). 
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Fig. 13. The effects of 10-6 Mand 10-5 M BTS 27271 on insulin secretion from the 
perfused rat pancreas. After baseline period of 10 min, BTS (shown in the heavy 
line) was given for 10 min, followed by 10 min of the washout period. At the end of 
experiment, 1 mM arginine was given for 10 min (shown in the heavy line). Values 
are shown as mean ± SE (n=3-5). 
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Fig. 14. A summary of BTS 27271-induced inhibition of insulin secretion. Values are shown a 
mean ± SE (n=3-5). *P<0.05, compared with the control group. 
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treatment and by using the corresponding area of the control groups as 100%, 
BTS 27271 (10-7 , 10-6 , or 10-5 M) significantly inhibited arginine-induced insulin 
secretion (Fig. 15). 
Effects of BTS 27271 on glucagon secretion 
BTS 27271 (10-9, 10-8, or 10-7 M) did not cause significant increases in 
glucagon secretion during the treatment and the washout periods (Figs. 16 and 17). 
However, BTS 27271 (10-7 M) enhanced arginine-induced glucagon secretion (Fig. 
16). BTS 27271 (10-6 and 10-5 M) significantly increased glucagon secretion with a 
peak of 275% and 228% of the baseline level, respectively. The effluent 
concentrations of glucagon remained high during the 10-min washout period in both 
groups (Fig. 18). Both concentrations of BTS 27271 significantly enhanced arginine-
induced glucagon secretion (Fig. 18). 
By calculating the area under the curve for the BTS 27271 treatment and by 
using the corresponding area of the control groups as 100%, BTS 27271(10-7,10-6 , 
or 10-5 M) significantly enhanced arginine-induced glucagon secretion in a 
concentration-dependent manner (Fig. 17). 
Effects of a-adrenergic receptor antagonists on amitraz-induced inhibition of 
insulin secretion 
Amitraz (10-5 M) alone inhibited insulin secretion by 45 ± 7% of baseline level 
(Fig. 6). Pretreatment of the pancreas with an a 2-AR antagonist idazoxan (10-8 M) 
for 10 min, did not significantly changed amitraz -induced inhibition of insulin 
secretion (Fig. 20), whereas idazoxan (10-7 and 10-5 M) antagonized the effect of 
amitraz on insulin secretion in a concentration-dependent manner (Figs. 20 and 22). 
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*P<0.05, compared with the control group. 
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Fig. 16. The effect of 10-9 M BTS 27271 on glucagon secretion from the perfused 
rat pancreas. After a baseline period of 10 min, BTS (shown in the heavy line) was 
given for 10 min, followed by 10 min of the washout period. At the end of the 
experiment, 1 mM arginine (shown in the heavy line) was given for 10 min. Values 
are shown as mean ± SE (n=3-4 ). 
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Fig. 17. The effects of 10-8 Mand 10-7 M BTS 27271 on glucagon secretion from 
the perfused rat pancreas. After a baseline period of 10 min, BTS (shown in the 
heavy line) was given for 10 min, followed by 10 min of the washout period. At the 
end of the experiment, 1 mM arginine (shown in the heavy line) was given for 10 
min. Values are shown as mean± SE (n=3-4). 
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Fig. 18. The effects of 10-6 Mand 10-5 M BTS 27271 on glucagon secretion from 
the perfused rat pancreas. After a baseline period of 10 min, BTS (shown in the 
heavy line) was given for 10 min, followed by 10 min of the washout period. At the 
end of the experiment, 1 mM arginine (shown in the heavy line) was given for 10 
min. Values are shown as mean± SE (n=3-4). 
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Fig. 20. The effects of ldazoxan (lda.)(10-8, 10-7, 10-6 M) (shown in the heavy line) 
on amitraz (A)(1 o-6 M)-induced insulin secretion from the perfused rat pancreas. 
After a pretreatment period of 10 min with idazoxan, amitraz (shown in the heavy 
line) was given for 10 min, followed by 10 min of the washout period. At the end of 
the experiment, 1 mM arginine (shown in the heavy line) was given for 10 min. 
Values are shown as mean± SE (n=4). 
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Fig. 21. The effects of prazosin (Pra.) (10-6 M) (shown in the heavy line) on amitraz 
(10-6 M)-induced inhibition of insulin secretion from the perfused rat pancreas. After 
a pretreatment period of 10 min with prazosin, amitraz (shown in the heavy line) was 
given for 10 min, followed by 10 min of the washout period. At the end of the 
experiment, 1 mM arginine (shown in the heavy line) was given for 10 min. Values 
are shown as mean± SE (n=4). 
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treatment and washout periods. Values are shown as mean± SE (n=4-5). *P<0.05, 
compared with the control group. 
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ldazoxan (10-7 M) abolished or attenuated this effect during the treatment and the 
washout periods, respectively (Figs. 20 and 22). ldazoxan (10-6 M) abolished the 
effect of amitraz during both the treatment and the washout periods (Figs. 20 and 
22). Prazosin (10-6 M), an a 1-AR antagonist, failed to antagonize the effect of 
amitraz (Fig . 21). By calculating the area under the curve for the arginine treatment 
and by using the corresponding area of the control groups as 100%, idazoxan (10-7 
and 10-6 M) abolished the inhibitory effect of amitraz (10-6 M) on 1 mM arginine-
induced insulin secretion (Fig. 23). 
Discussion 
This is the first study to demonstrate the direct effect of amitraz and BTS 
27271, the active metabolite of amitraz, on insulin and glucagon secretion from the 
pancreas. These results are consistent with the findings of previous in vivo (Hsu 
and Kakuk, 1984; Hsu et al., 1986; Schaffer et al., 1990; Reynoldson and Cullen, 
1997) and clonal ~-cell (Chen and Su, 1994) studies with respect to the effects of 
amitraz and BTS 27271 on insulin secretion. 
Amitraz and BTS 27271 (10-8 - 10-5 M) caused a concentration-dependent 
inhibition of insulin secretion, and the effect of BTS 27721 was slightly more potent 
than that of amitraz. These results are consistent with those of another study that 
demonstrated the inhibitory effect of amitraz and BTS 27271 on insulin secretion 
from a rat p-cell line RINm5F (Chen and Hsu, 1994). The other metabolites of 
amitraz were not examined in the present study, as it is known that BTS 27271 is the 
only metabolite of amitraz that inhibits insulin secretion from RINm5F cells (Chen 
and Hsu, 1994). BTS 27271 has been found to be more potent than amitraz with 
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Fig. 23. A summary of 1 mM arginine-induced insulin secretion in groups that were 
previously exposed to a-adrenoceptor antagonist (ldazoxan (Ida.) or Prazosin (Pra.)) 
and amitraz (A). Values are shown as mean ±SE (n=4-5). *P<0.05, compared with 
the control group. 
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regard to miticidal activity (Schuntner and Thompson, 1987) and mammalian toxicity 
(Pass and Mogg, 1991 ). 
Amitraz and BTS 27271 increased glucagon secretion and enhanced 
arginine-induced glucagon secretion. These results were not unexpected since 
other studies showed that a2-AR agonists such as oxymetazoline and clonidine 
stimulate glucagon secretion (Gotoh et al., 1988; Hirose et al, 1992; 1993a; 1993b). 
However, it is clear from these results that the effect of amitraz and BTS 27271 on 
insulin secretion is more potent than that on glucagon secretion. 
Amitraz is a highly-lipid soluble compound; which is rapidly absorbed through 
cutaneous tissues (Hsu and Schaffer, 1988; Dobozy, 1990; Aydin et al., 1997), and 
thus, it is potentially hazardous to veterinarians, animal caretakers, and pet owners. 
Over sixteen cases of amitraz toxicity in humans in which hyperglycemia was the 
most prominent sign have been reported (FDA Veterinarian, 1989; Ros and Aken , 
1994; Kennel et al. , 1996; Jorens et al.; 1997; and Aydin et al., 1997). Since 
hyperglycemia is found in most of the human cases of amitraz poisoning, exposure 
to this pesticide would be expected to pose a greater hazard to patients with type II 
diabetes, who already have impaired insulin secretion and/or utilization. a2-AR 
agonists cause a greater suppression of insulin secretion from human patients with 
type II diabetes than from normal subjects (Okada et al. , 1986; and Koev et al., 
1989). Exposure of patients with type II diabetes to amitraz and its active metabolite 
may reduce their insulin secretion and further hamper glucose metabolism. 
In both the amitraz and the BTS 27271 treated groups, the inhibition of insulin 
secretion persisted. The effluent insulin concentrations remained low during the 10-
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min washout period, although they were expected to return to baseline level after the 
washout of the pesticide. To answer the question whether this effect is due to 
insufficient washout time, we prolonged the washout period to 20-min, however, the 
effluent concentrations remained low and did not return to the baseline level (data 
not shown). We speculate that this phenomenon may be due to a high binding 
affinity of amitraz and BTS 27271 to their receptors. The effluent concentrations of 
glucagon also remained high during the 10-min washout period for both the amitraz 
and the BTS 27271 treated groups. In vivo administration of amitraz caused a dose-
dependent inhibition of 3H-clonidine to a 2-ARs in rat brain, and the recovery of 3H-
clonidine binding occurred only 72 h following amitraz administration (Costa et al., 
1988). The persistent effect of amitraz and BTS 27271 on the secretion of insulin 
and glucagon should prompt careful handling of this pesticide to avoid the toxicity. 
By calculating the area under the curve for the arginine treatment and by 
using the corresponding area of the control groups as 100%, amitraz and BTS 
27271 (1 o-7, 10-6, or 10-5 M) significantly inhibited arginine-induced insulin secretion. 
However, when insulin secretion was expressed as the percentage increase above 
the pre-arginine value, the groups that had been previously exposed to amitraz and 
BTS 27271 were not significantly different from the control groups. All groups had 
~ 200% increase over the baseline level in response to 1 mM arginine. Thus, the 
effect of amitraz and BTS 27271 on arginine-induced insulin secretion depends upon 
how the data are expressed. 
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ldazoxan, an a2A120-AR antagonist, blocked the inhibitory effect of amitraz on 
insulin secretion in a concentration-dependent manner, but prazosin, an a 1- and 
a2812c-AR antagonist, failed to antagonize the effect of amitraz. These results 
suggest that a2A/2o-ARs mediate the inhibitory effects of amitraz on insulin secretion. 
Our present findings are consistent with those of the previous reports in which a 2-
ARs mediate the actions of amitraz in animals (Hsu and Kakuk, 1984; Hsu et al., 
1986; Schaffer et al., 1990; Reynoldson and Cullen, 1996) and a p-cell line (Chen 
and Hsu, 1994). The a2A120-ARs are orthologs, i.e., a species may have either a2A or 
a20 but not both; rodents have a20-ARs, but not a2A-ARs (O'Rourke et al, 1994). 
Thus a 20-ARs should be the receptors that mediate the inhibition of insulin in 
rodents. 
We did not study the effect of idazoxan or prasozin on the amitraz induced-
increase in glucagon secretion, because we used amitraz at a concentration of 10-5 
M, which decreased insulin secretion by 45 ± 7% of the baseline level but did not 
cause significant increases in glucagon secretion. We intended to use amitraz (10-5 
M) for the antagonism study, but idazoxan (10-6 M) failed to antagonize the effects of 
amitraz at this concentration (data not shown). 
lmidadozline binding sites on pancreatic p-cells have been reported 
(Remaury and Herve, 1992; Chan et al., 1995; Morgan et al., 1995). Many a 2-AR 
agonists (e.g., oxymetazoline and clonidine), a2-AR antagonists (e.g., efaroxan, DG-
5128, and idazoxan), and the nonselective a-AR antagonist phentolamine are 
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imidazoline compounds. It is well established that imidazoline compounds such as 
phentolamine (Schulz and Hasselblatt, 1989), efraroxan (Chan and Morgan, 1990), 
and DG-5128 (Chan et al. , 1991) stimulate insulin secretion. In the present study 
idazoxan (~10-6 M), failed to stimulate insulin secretion. These results are consistent 
with those of another study that demonstrated that idazoxan failed to alter insulin 
secretion or arginine-induced glucagon secretion (Mourtada et al., 1997). 
Conclusion 
Our findings suggest that amitraz inhibits insulin secretion by the activation of 
a2N 2o-ARs. Amitraz and BTS 27271 inhibit arginine-induced insulin secretion and 
enhance arginine-induced glucagon secretion. These effects may result from the 
high binding affinity of amitraz and BTS 27271 to the a2-ARs of the pancreatic islets. 
Since amitraz exerts a2-AR agonistic activities, specific a 2-AR antagonists may be 
useful in treating amitraz toxicity including hyperglycemia and hypoinsulinemia. The 
results of several human studies indicate a possible role of the a2-adrenegic 
receptors in the impaired p-cell function in type II diabetic patients (Robertson et al., 
1976, Kashiwagi et al , 1986, Ortiz-Alonso et al. , 1991). It is likely that these patients 
are more sensitive to amitraz than normal subjects. Further studies are needed to 
prove or disprove this hypothesis. 
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